###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT </italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 254 255 254 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 321 325 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">para</italic>
###xml 466 470 466 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT </italic>
###xml 238 243 <span type="species:ncbi:9606">human</span>
###xml 460 465 <span type="species:ncbi:9606">human</span>
Alzheimer's disease is multifactorial, having environmental, toxicological and genetic risk factors. Impaired folate and homocysteine metabolism has been hypothesised to increase risk. In addition to its xenobiotic-metabolising capacity, human arylamine N-acetyltransferase type-1 (NAT1) acetylates the folate catabolite para-aminobenzoylglutamate and is implicated in folate metabolism. The purpose of this study was to determine whether polymorphisms in the human NAT genes influence susceptibility to Alzheimer's disease.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 126 131 126 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
Elderly individuals with and without Alzheimer's disease were genotyped at the polymorphic NAT1 (147 cases; 111 controls) and NAT2 (45 cases; 63 controls) loci by polymerase chain reaction-restriction fragment length polymorphism, and the genotype and allele frequencies were compared using the chi-squared test.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 114 127 114 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10/1*10 </italic>
###xml 247 252 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 253 255 253 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 273 275 273 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 370 378 370 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11B</italic>
Although a trend towards fast NAT2 acetylator-associated Alzheimer's disease susceptibility was indicated and the NAT1*10/1*10 genotype was observed only in cases of Alzheimer's disease (6/147, 4.1%), no significant difference in the frequency of NAT2 (p = 0.835) or NAT1 (p = 0.371) genotypes was observed between cases and controls. In addition, a novel NAT1 variant, NAT1*11B, was identified.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 164 172 164 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 269 278 269 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11A </italic>
###xml 286 295 286 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11B </italic>
These results suggest that genetic polymorphisms in NAT1 and NAT2 do not influence susceptibility to Alzheimer's disease, although the increase in frequency of the NAT1*10 allele in Alzheimer's disease is worthy of further investigation. Due to its similarity with the NAT1*11A allele, NAT1*11B is likely to encode an enzyme with reduced NAT1 activity.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 331 334 328 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 337 338 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 360 363 357 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PS1</italic>
###xml 366 367 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 389 392 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PS2</italic>
###xml 395 396 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 420 424 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOE</italic>
###xml 427 428 424 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 600 601 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 682 683 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 684 685 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 949 950 946 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
Alzheimer's disease (AD) is a common multifactorial disease of the elderly, which results in progressive neurodegeneration causing severe and permanent cognitive impairment [1]. As a result of family pedigree analyses and case-control studies, multiple genetic risk factors such as mutations in the beta-amyloid precursor protein (APP) [2], presenilin type-1 (PS1) [3], presenilin type-2 (PS2) [4] and apolipoprotein E (APOE) [5] genes have been identified. Genetic epidemiology studies have however, estimated that only 30% to 50% of the population risk for AD can be attributed to genetic factors [6]. This along with the low concordance rate of AD observed in monozygotic twins [7,8] suggests that environmental factors may also influence AD susceptibility. This may be the case particularly for later-onset 'sporadic' cases of the disease, which account for the majority (approximately 90%) of AD cases but show only modest familial clustering [6].
###end p 10
###begin p 11
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 559 561 559 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Many putative environmental risk factors for AD have been proposed. In particular, low blood levels of folate and elevated serum total homocysteine have been associated with increased risk of AD [9-11]. Differences in the level of serum homocysteine and folate were not associated with increasing duration of the symptoms of AD [10], which suggests that the observed level of these biochemical markers was not due to progression of the disease. Therefore, impaired folate and homocysteine (one-carbon) metabolism has been hypothesised as a risk factor in AD [10]. Such altered folate and homocysteine metabolism could arise as a result of genetic mutations in enzymes of folate metabolism.
###end p 11
###begin p 12
###xml 206 207 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 857 862 857 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 150 155 <span type="species:ncbi:9606">human</span>
###xml 248 254 <span type="species:ncbi:10090">murine</span>
###xml 354 360 <span type="species:ncbi:10090">murine</span>
###xml 482 487 <span type="species:ncbi:10090">mouse</span>
###xml 555 560 <span type="species:ncbi:9606">human</span>
###xml 606 611 <span type="species:ncbi:9606">human</span>
###xml 622 627 <span type="species:ncbi:9606">human</span>
###xml 642 648 <span type="species:ncbi:10090">murine</span>
###xml 734 739 <span type="species:ncbi:9606">Human</span>
The association between impaired folate and homocysteine metabolism and AD is particularly interesting in view of the putative endogenous role of the human phase II xenobiotic-metabolising enzyme arylamine N-acetyltransferase type-1 (NAT1)(and its murine homologue NAT2), in folate catabolism [12-15], and our previous demonstration of the expression of murine NAT2 in particular cell types, such as the cytoplasm and dendrites of the Purkinjie cells of the cerebellum in the adult mouse brain [16]. There has as yet been no description of the pattern of human NAT1 expression in the adult brain, although human NAT1 (the human equivalent of murine NAT2) activity has been identified in the brain early in embryonic development [17]. Human NAT1 is polymorphic [18] and inter-individual variation in NAT1 activity [19] may modulate individual folate levels. NAT1 may therefore be a potential low penetrance gene which can modify individual risk of AD.
###end p 12
###begin p 13
###xml 31 32 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2</italic>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 984 989 984 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 993 998 993 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 1031 1036 1031 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 1040 1045 1040 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 480 485 <span type="species:ncbi:9606">human</span>
###xml 508 513 <span type="species:ncbi:9606">human</span>
###xml 765 770 <span type="species:ncbi:9606">human</span>
Polymorphisms in the arylamine N-acetyltransferase type-2 (NAT2) gene, which encodes the phase II xenobiotic-metabolising isozyme NAT2, have been linked with increased susceptibility to multifactorial neurodegenerative disorders such as Parkinson's disease [20,21]. In this case the impaired ability of the individual to handle environmental xenobiotics or neurotoxins acting on the brain has been hypothesised to contribute to the development of the disease. In a similar manner human NAT2, and in addition human NAT1, in their more traditionally recognized role as phase II xenobiotic-metabolising enzymes [22], may also be modulators of AD risk as a result of chemical insult. An association study carried out by Rocha et al., [23] has previously indicated that human NAT2 may be a potential low penetrance gene in AD pathogenesis. In view of these findings we undertook a study to genotype an elderly group of individuals with and without a history of AD for major alleles at the NAT1 and NAT2 loci, to investigate the role of NAT1 and NAT2 polymorphisms in AD susceptibility.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Study populations
###end title 15
###begin p 16
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 551 563 551 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post mortem </italic>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1382 1383 1382 1383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1386 1397 1386 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Post mortem</italic>
###xml 1566 1568 1566 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 2011 2022 2011 2022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post mortem</italic>
###xml 2202 2214 2202 2214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post mortem </italic>
###xml 2288 2299 2288 2299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post mortem</italic>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 1653 1661 <span type="species:ncbi:9606">patients</span>
###xml 1719 1727 <span type="species:ncbi:9606">patients</span>
###xml 1823 1831 <span type="species:ncbi:9606">patients</span>
###xml 1937 1944 <span type="species:ncbi:9606">patient</span>
Genomic DNA from 148 elderly Caucasian individuals with AD and 90 elderly Caucasian individuals without AD, from the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort, was available for investigation. OPTIMA is a longitudinal study of normal, non-institutionalised elderly volunteers with good cognitive function, and elderly patients with memory problems from the Oxfordshire community (UK), and has been described in detail elsewhere [10,24]. Briefly, the OPTIMA study follows the AD course of an individual, from initial diagnosis to post mortem confirmation. Every year each subject is examined by neurological and neuropsychological tests, brain scans and biochemical analysis of blood and cerebrospinal fluid. Cognitive evaluation is undertaken using the Cambridge Examination for Mental Disorders of the Elderly [25]. This includes the Cambridge Cognitive Examination (CAMCOG), a neuropsychological test which includes elements of the Mini-Mental State Examination and assesses a broad range of cognitive functions, such as memory, language, attention, perception, praxis and thinking. A cut-off value of <80/107 CAMCOG points discriminates between demented and normal subjects. Clinical diagnosis is made according to the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association criteria [1]. Post mortem, the brain is examined by histochemical and biochemical methods to confirm disease pathology using Consortium to Establish a Registry for Alzheimer's Disease criteria [26]. In this study the AD case individuals from the OPTIMA cohort included: 101 living patients with a clinical diagnosis of probable or possible AD, 30 patients with histologically confirmed pure AD with the absence of any additional disease pathology, 16 patients with histologically confirmed AD with the coexistence of vascular or Parkinson's disease pathology and 1 patient who demonstrated clinical symptoms of AD which were not confirmed post mortem. The non-demented control individuals from the OPTIMA cohort included: 83 living subjects with no clinically diagnosed symptoms of AD, 4 subjects with the absence of AD confirmed post mortem and 3 subjects who demonstrated no symptoms of AD which was not confirmed post mortem. The OPTIMA study had ethical approval from the central Oxford and Psychiatric Research Ethics Committees and informed consent was obtained in writing from all subjects.
###end p 16
###begin p 17
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 619 621 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 849 851 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 483 495 <span type="species:ncbi:9606">Participants</span>
Genomic DNA from 22 elderly volunteers from the Foresight Challenge cohort was also available for investigation. Foresight Challenge is a cohort of normal, non-institutionalised elderly volunteers with good cognitive function from the Oxfordshire community (UK)(non-black and Caucasian), recruited for a three-year longitudinal study aimed at further defining early markers or predictors of cognitive impairment and their relationship to the subsequent development of dementia [27]. Participants were excluded if they: (a) scored </=80/107 points on the CAMCOG or </=24/30 points on the Mini-Mental State Examinations [25] at the initial screening visit, (b) reported significant progressive subjective memory complaints, (c) lived in institutional care, or (d) were unable to complete the Cambridge Examination for Mental Disorders of the Elderly [25]. For the purpose of this study the individuals in the case and control groups were regarded as homogeneous groups. Subjects with other causes of dementia were excluded from the study.
###end p 17
###begin title 18
Materials
###end title 18
###begin p 19
All chemicals were purchased from Sigma-Aldrich Company Ltd., Merck Ltd. or BDH Laboratory Supplies, UK. Molecular biology reagents were purchased from Promega, Roche Molecular Biochemicals and New England Biolabs Inc., UK. Oligonucleotides were synthesized by Sigma-Genosys Ltd., UK.
###end p 19
###begin title 20
DNA extraction
###end title 20
###begin p 21
###xml 31 33 31 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 53 55 53 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 122 124 122 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 241 245 241 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 363 364 355 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Genomic DNA from each AD case (n = 148) and control (n = 90) subject in the OPTIMA cohort, and from each control subject (n = 22) in the Foresight Challenge cohort was prepared from the buffy coat fraction of EDTA blood [28] using the Wizard(R) Genomic DNA Purification Kit (Promega, UK), and was stored at 4degreesC in TE buffer (10 mM Tris-HCl (pH 7.5), 1 mM Na2EDTA).
###end p 21
###begin title 22
NAT1 genotyping
###end title 22
###begin p 23
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*3</italic>
###xml 18 24 18 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4</italic>
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10</italic>
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11A </italic>
###xml 48 57 48 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14A </italic>
###xml 88 92 88 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT </italic>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 416 417 416 417 <underline xmlns:xlink="http://www.w3.org/1999/xlink">T</underline>
###xml 457 458 457 458 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 481 485 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo </italic>
###xml 534 540 534 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*3</italic>
###xml 542 550 542 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 554 563 554 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14A </italic>
###xml 627 631 627 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo </italic>
###xml 639 647 639 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11A</italic>
###xml 768 772 768 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo </italic>
###xml 785 792 785 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 868 875 868 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*3 </italic>
###xml 898 906 898 906 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 910 919 910 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14A </italic>
###xml 946 954 946 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 958 967 958 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14A </italic>
###xml 1022 1025 1022 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsa</italic>
###xml 1030 1032 1030 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1074 1081 1074 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human NAT1*3, NAT1*4, NAT1*10, NAT1*11A and NAT1*14A alleles (those unfamiliar with NAT allele nomenclature should see ) were identified by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and allele-specific PCR (AS-PCR) step-by-step genotyping procedure [29]. To summarise, a fragment of 344 bp between nucleotides 769 and 1113 was amplified with primers N769 (5'-ACTCTGAGTGAGGTAGAAATA-3') and N1113 (5'-ACAGGCCATCTTTAGAA-3'). As a result of Mbo II sites at nucleotides 945 and 969, the alleles NAT1*3, NAT1*10 and NAT1*14A produce fragments of 176 bp, 24 bp and 144 bp on digestion with Mbo II (for NAT1*11A, as a result of a 9 bp deletion, the fragments are 176 bp, 24 bp and 135 bp). The primer N1113 introduces an additional Mbo II site into NAT1*4 such that the 144 bp fragment is cleaved to 125 bp and 19 bp. Subsequently, NAT1*3 was distinguished from NAT1*10 and NAT1*14A by an allele-specific PCR. NAT1*10 and NAT1*14A were distinguished by a further PCR and digestion with BsaO I [29]. Nucleotides which are changed from the NAT1*4 sequence (EMBL Accession Number AJ307007) are underlined.
###end p 23
###begin p 24
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14A </italic>
###xml 93 102 93 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14B </italic>
###xml 207 215 207 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 219 228 219 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14A </italic>
###xml 425 427 424 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 447 451 446 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 521 523 520 522 <underline xmlns:xlink="http://www.w3.org/1999/xlink">CG</underline>
###xml 560 561 559 560 <underline xmlns:xlink="http://www.w3.org/1999/xlink">T</underline>
###xml 567 568 566 567 <underline xmlns:xlink="http://www.w3.org/1999/xlink">T</underline>
###xml 751 759 738 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 763 772 750 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14A </italic>
###xml 973 976 959 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsa</italic>
###xml 1023 1025 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1028 1037 1014 1023 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*14A </italic>
###xml 1066 1069 1052 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsa</italic>
###xml 1093 1101 1079 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 1128 1131 1114 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bsa</italic>
The NAT1*14A allele (G560A, T1088A, C1095A) was confirmed and distinguished from the similar NAT1*14B allele (G560A), by further analysis using AS-PCR and nested PCR-RFLP. This analysis first amplified only NAT1*10 and NAT1*14A allele sequences, and then identified whether the G560A variation was present. AS-PCR amplification was performed in a 100 mul reaction using 1X PCR reaction buffer, 250 ng genomic DNA, 2.5 mM MgCl2 0.2 mM dNTPs, 2.5 U Taq DNA polymerase and 25 pmoles each of primers N539 (5'-TCCTAGAAGACAGCAACGACC-3') and N1110b (5'-GGCCATCTTTAAAATACATTTT-3')(with annealing temperature 54degreesC and a product extension of 1 minute at 72degreesC). Primer N1110b, which contains T1088 annealed to and amplified a 571 bp product from the NAT1*10 and NAT1*14A allele sequences only. The PCR product from the first round of amplification was diluted 1 in 20, and 1 mul used as template in a PCR with primers N539 and N714 (5'-GTGAAGCCCACCAAACAG-3'), followed by BsaO I digestion of the 175 bp amplified product [29]. NAT1*14A contains G560A; therefore no BsaO I site was generated. NAT1*10 contains G560, therefore a BsaO I site was generated resulting in fragments of 155 bp and 20 bp.
###end p 24
###begin title 25
NAT2 genotyping
###end title 25
###begin p 26
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4</italic>
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5A</italic>
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5B</italic>
###xml 36 43 36 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5C</italic>
###xml 45 53 45 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*6A </italic>
###xml 57 65 57 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*7B </italic>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 343 349 343 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4</italic>
###xml 350 358 350 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5B </italic>
###xml 366 373 366 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5A</italic>
###xml 374 382 374 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5C </italic>
###xml 438 445 438 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4 </italic>
###xml 462 470 462 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5B </italic>
###xml 568 576 568 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5A </italic>
###xml 595 603 595 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5C </italic>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 725 731 725 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4</italic>
###xml 732 740 732 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5B </italic>
###xml 781 786 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 790 795 790 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human NAT2*4, NAT2*5A, NAT2*5B, NAT2*5C, NAT2*6A and NAT2*7B alleles were identified by genotyping using the PCR-RFLP method of Hickman & Sim [30], and Hickman et al. [31]. This method is more than 95% accurate at predicting the NAT2 phenotype in a Caucasian population [31]. This method of genotyping is unable to distinguish between the NAT2*4/NAT2*5B and the NAT2*5A/NAT2*5C genotypes. However, since the expected frequency of the NAT2*4 (19% to 27%) and NAT2*5B (38% to 45%) alleles in a Caucasian population is much greater than the expected frequency of the NAT2*5A (1.0% to 4.2%) and NAT2*5C (1.0% to 4.3%) alleles [32], this method is sufficient to confer an accurate genotype in greater than 99% of cases if the NAT2*4/NAT2*5B genotype is inferred. Genotyping of both NAT1 and NAT2 was carried out blind with respect to the disease status of the subjects.
###end p 26
###begin title 27
Sequencing of novel NAT1 variant
###end title 27
###begin p 28
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 180 184 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfu </italic>
###xml 217 221 215 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pfu </italic>
###xml 266 267 264 265 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 584 587 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 670 678 654 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 941 946 920 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 972 977 951 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 1015 1020 994 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 1187 1191 1166 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1</italic>
###xml 670 677 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
PCR amplification of a 1614 nucleotide region of NAT1 for cloning and sequencing of a NAT1 variant was performed in a 100 mul reaction using 1 mug genomic DNA, 2.5 U high-fidelity Pfu DNA Polymerase (Promega, UK), 1X Pfu DNA Polymerase reaction buffer with 2 mM MgSO4, 0.2 mM dNTPs, and 25 pmoles each of primers N-438 (5'-TTGTATAAGGCTCAGCTAAAAGGG-3') and N1176 (5'-GGAATTCAACAATAAACCAACAT-3')(with annealing temperature 56degreesC and a product extension of 2 minutes at 72degreesC). Following gel purification, the amplified PCR product was A-tailed with dATP, ligated into the pGEM(R)-T Easy Vector (Promega, UK), and transformed into high efficiency JM109 Competent E. coli cells (Promega, UK) by heat shock. Positive clones were identified by blue-white selection on LB agar plates containing 100 mug/ml ampicillin, 0.1 mM isopropyl-beta-D-thiogalactoside (Melford Laboratories Ltd., UK) and 40 mug/ml X-Gal. The identity of the cloned NAT1 sequence was confirmed by NAT1 genotyping of plasmid DNA. The cloned NAT1 inserts (two different clones for each allele) were sequenced using M13F (5'-AGGGTTTTCCCAGTCACGA-3') and M13R (5'-ACACAGGAAACAGCTATGAC-3') sequencing primers, and the NAT1-specific primer N714. Fluorescent DNA sequencing was performed by the DNA Sequencing Facility, Department of Biochemistry, University of Oxford, using an ABI 377XL Prism DNA Sequencer with ABI BigDyetrade mark terminators (Warrington, UK). Sequencing chromatograms were analysed using Chromas version 1.45 (Conor McCarthy, Griffith University, Australia).
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT </italic>
###xml 95 99 95 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT </italic>
###xml 272 276 272 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT </italic>
###xml 390 392 390 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 516 520 516 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT </italic>
NAT allele and genotype frequencies for the AD case and control groups were calculated and the NAT genotype distribution for AD case and control groups was tested for Hardy-Weinberg equilibrium. Any deviations from this equilibrium were assessed using a chi-squared test. NAT allele and genotype distributions of the AD case and control groups were compared using the chi-squared test, and p values of less than 0.05 were considered to be significant. The strength of association between inheritance of a particular NAT allele or genotype and AD was assessed by calculation of crude odds ratios (OR) and 95% confidence intervals (CI).
###end p 30
###begin title 31
Results
###end title 31
###begin p 32
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 68 70 68 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 100 102 100 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 275 282 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 340 348 340 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
The NAT1 genotype of each individual in the Alzheimer's case group (n = 147) and the control group (n = 111) was determined and the frequency of NAT1 alleles and NAT1 genotypes is illustrated in Table 1 and Table 2 respectively. The distribution of alleles demonstrates that NAT1*4 is the most common allele in both groups (75-79%), whilst NAT1*10 is the next most frequent (15-19%). The same pattern has been observed in all Caucasian populations that have been studied [32]. The genotypes observed were determined to be in Hardy-Weinberg equilibrium.
###end p 32
###begin p 33
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
NAT1 allele frequency in AD cases and controls.
###end p 33
###begin p 34
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 174 181 174 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
The number and frequency (in brackets) of NAT1 alleles in 147 AD cases and 111 controls is shown. The OR of AD to non-disease is given with 95% CI for each NAT1 allele (with NAT1*4 as the reference group).
###end p 34
###begin p 35
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
NAT1 genotype frequency in AD cases and controls.
###end p 35
###begin p 36
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 272 275 272 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1*4</italic>
###xml 277 280 277 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1*3</italic>
###xml 282 286 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1*10</italic>
###xml 288 294 288 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1*11A </italic>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1*14A </italic>
###xml 444 449 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 464 478 464 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4/NAT1*4 </italic>
The number and frequency (in brackets) of NAT1 genotypes in 147 AD cases and 111 controls is shown. Expected genotype frequency was calculated based on the allele frequency in the control group (Table 1). 'Others' includes additional NAT1 genotypes containing the alleles 1*4, 1*3, 1*10, 1*11A and 1*14A expected at low frequency which were not observed in these AD cases and controls. The OR of AD to non-disease is given with 95% CI for each NAT1 genotype (with NAT1*4/NAT1*4 as the reference group).
###end p 36
###begin p 37
###xml 175 177 173 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 185 187 183 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 202 204 198 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 212 214 208 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 250 258 246 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 340 348 336 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 626 634 622 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 693 695 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 306 313 <span type="species:ncbi:9606">patient</span>
Although a chi-squared comparison of the two groups being investigated demonstrates that the allele and genotype frequency of the two groups does not differ significantly (chi2 = 1.84, p = 0.765 and chi2 = 6.48, p = 0.371 respectively) the number of NAT1*10 alleles is slightly elevated in the Alzheimer's patient population. Comparing the NAT1*10 homozygote genotype frequency, there are 6 out of 147 Alzheimer's cases with this genotype, whilst there are no control individuals with this genotype out of 111 investigated. Although the numbers are small, it is a finding worthy of further investigation, especially since the NAT1*10 allele may have an effect on the level of NAT1 expression [33].
###end p 37
###begin p 38
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 70 72 70 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 99 101 99 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 252 260 252 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5B </italic>
###xml 318 326 318 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*6A </italic>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 476 481 476 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 612 614 610 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 622 624 620 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 639 641 635 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 649 651 645 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 803 808 799 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 818 820 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 943 944 939 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 1208 1210 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1314 1316 1308 1310 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1324 1326 1318 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1485 1487 1479 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1508 1510 1502 1504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1727 1729 1721 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1730 1732 1724 1726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
NAT2 genotyping was carried out on a random subgroup of the AD cases (n = 45) and of the controls (n = 63). The frequency of NAT2 alleles and NAT2 genotypes (which were in Hardy-Weinberg equilibrium) is illustrated in Table 3 and Table 4 respectively. NAT2*5B is the most common allele in both groups (39-42%), whilst NAT2*6A is the next most frequent allele (31-36%), as seen in other Caucasian populations that have been studied [32]. A direct chi-squared comparison of the NAT2 allele and genotype frequencies in the Alzheimer's case and control groups indicates that they are not significantly different (chi2 = 1.95, p = 0.857 and chi2 = 5.76, p = 0.835 respectively). In a Caucasian population, an individual's NAT2 phenotype can be predicted quite accurately (in more than 95% of cases) by their NAT2 genotype [31]. Therefore the Alzheimer's cases and control individuals were classified as fast or slow acetylators and compared (Table 5). Although a small increase in the frequency of the NAT2 fast acetylator phenotype was observed in the AD cases (38%) compared with the controls (35%), which is in agreement with a similar study carried out in a Portuguese sporadic AD population by Rocha et al. [23], once again no significant difference between the Alzheimer's case and control group was observed (chi2 = 0.09, p = 0.761). Other studies have also demonstrated a lack of association between the NAT2 acetylator phenotype and risk of AD including those by Steventon et al. [34] and Ladero et al. [35]. However, in these cases it has been suggested that administration of therapeutic agents such as tacrine, an acetylcholinesterase inhibitor used in the treatment of AD, which is thought to be metabolised by CYP1A2 [36,37] may have affected the acetylation of sulphamethazine which was used to phenotype NAT2.
###end p 38
###begin p 39
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
NAT2 allele frequency in AD cases and controls.
###end p 39
###begin p 40
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 154 159 154 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 172 179 172 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4 </italic>
The number and frequency (in brackets) of NAT2 alleles in 45 AD cases and 63 controls is shown. The OR of AD to non-disease is given with 95% CI for each NAT2 allele (with NAT2*4 as the reference group).
###end p 40
###begin p 41
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
NAT2 genotype frequency in AD cases and controls.
###end p 41
###begin p 42
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 232 237 232 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 270 273 270 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2*4</italic>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2*5A</italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2*5B</italic>
###xml 287 291 287 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2*5C</italic>
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2*6A </italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">2*7B </italic>
###xml 447 452 447 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 467 481 467 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4/NAT2*4 </italic>
The number and frequency (in brackets) of NAT2 genotypes in 45 AD cases and 63 controls is shown. Expected genotype frequency was calculated based on the allele frequency in the control group (Table 3). 'Others' includes additional NAT2 genotypes containing the alleles 2*4, 2*5A, 2*5B, 2*5C, 2*6A and 2*7B expected at low frequency which were not observed in these AD cases and controls. The OR of AD to non-disease is given with 95% CI for each NAT2 genotype (with NAT2*4/NAT2*4 as the reference group).
###end p 42
###begin p 43
NAT2 phenotype distribution in AD cases and controls.
###end p 43
###begin p 44
###xml 269 276 269 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4 </italic>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 369 376 369 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5A</italic>
###xml 378 385 378 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5B</italic>
###xml 387 394 387 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*5C</italic>
###xml 396 404 396 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*6A </italic>
###xml 408 415 408 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*7B</italic>
###xml 473 475 473 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
The number and frequency (in brackets) of fast and slow NAT2 acetylators in 45 AD cases and 63 controls is shown. Based on their genotype, AD cases and controls were classified as either 'fast' or 'slow' NAT2 acetylators. Individuals homozygous or heterozygous for the NAT2*4 allele were assigned fast NAT2 acetylators, individuals who carried two 'slow' NAT2 alleles (NAT2*5A, NAT2*5B, NAT2*5C, NAT2*6A and NAT2*7B) in any combination were assigned slow NAT2 acetylators [31]. The OR of AD to non-disease is given with 95% CI for each NAT2 phenotype (with NAT2 fast acetylator as the reference group).
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 285 290 285 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 512 517 512 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 848 856 848 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 1073 1080 1073 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4 </italic>
It is hypothesized that variation in NAT1 activity may alter the risk of AD (which has been associated with low blood folate levels [9-11]), via the postulated role of NAT1 in folate metabolism. Together, the results of the present study suggest that genetic polymorphisms in NAT1 and NAT2 do not influence susceptibility to AD. It should be noted that the study presented here is preliminary and its statistical power is limited due to the relatively small number of samples analysed, particularly the study of NAT2 genotype and risk of AD. Therefore much larger case-control investigations, using more highly automated detection methods such as the LightCycler real-time PCR methods of Blomeke et al. [38] and Wikman et al. [39] will help to validate the results shown here. In order to detect a 1.5 fold increased risk of AD associated with the NAT1*10 allele, approximately 650 cases and 650 controls would need to be studied to give 80% power of achieving significance at the 5% level. Similarly, in order to detect a 1.5 fold increased risk of AD associated with the NAT2*4 allele, approximately 520 cases and 520 controls would need to be studied.
###end p 46
###begin p 47
It is hypothesised that expression of a high activity NAT2 enzyme might increase the metabolic activation of environmental compounds (including neurotoxins), contributing to the neuronal tissue degeneration characteristic of AD. However, as no environmental compounds or neurotoxins currently suspected of contributing to the development of AD are known to be metabolised by the NAT enzymes, the identification of endogenous NAT substrates or NAT substrates which may be precursors of neurotoxic derivatives, will be important to strengthen the hypothesis that NAT1 and NAT2 may be risk factors for AD as a result of chemical insult.
###end p 47
###begin p 48
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">para</italic>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 357 361 357 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2</italic>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 848 853 848 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 312 318 <span type="species:ncbi:10090">murine</span>
###xml 338 343 <span type="species:ncbi:9606">human</span>
###xml 350 356 <span type="species:ncbi:10090">murine</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 476 482 <span type="species:ncbi:10090">murine</span>
###xml 671 677 <span type="species:ncbi:10090">murine</span>
###xml 798 802 <span type="species:ncbi:10090">mice</span>
###xml 817 821 <span type="species:ncbi:10090">mice</span>
###xml 842 847 <span type="species:ncbi:9606">human</span>
At present, the suggestion for an endogenous role for human NAT1 has focused on the ability of human NAT1 to acetylate the folate catabolite para-aminobenzoylglutamate [12,13]. However, it is possible that NAT1 may play a role in the metabolism of other, as yet unidentified arylamines. Experiments in which the murine gene equivalent to human NAT1 (murine NAT2) has been knocked out indicate that superficially the mice are well [40]. However, in view of the distribution of murine NAT2 in the nervous system [16], it is important that subtle tests involving behaviour are carried out and the histology of the nervous system is studied in order to determine the role of murine NAT2 in the nervous system and identify whether there might be compensating factors at play in the genetically modified mice. In addition, mice over-expressing the human NAT1 gene show developmental abnormalities [41].
###end p 48
###begin p 49
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 158 165 158 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo </italic>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4</italic>
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1(a)</xref>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 550 554 550 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo </italic>
###xml 627 634 627 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11</italic>
###xml 969 974 969 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 1105 1114 1105 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11B </italic>
###xml 1172 1181 1172 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11A </italic>
###xml 1206 1210 1206 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1(b)</xref>
###xml 1213 1222 1213 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11B </italic>
###xml 1265 1272 1265 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 1463 1472 1463 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11A </italic>
###xml 1592 1594 1592 1594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1595 1597 1595 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1648 1655 1648 1655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 1693 1697 1693 1697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1(b)</xref>
###xml 1793 1800 <span type="species:ncbi:9606">patient</span>
Whilst identifying the NAT1 alleles, a pattern was observed in one individual that was not consistent with any known NAT1 genotype. Only individuals with the NAT1*4 allele generate restriction fragments of 176 bp and 125 bp following PCR amplification of the region corresponding to nucleotides 769 to 1113, and digestion with the restriction enzyme Mbo II. This allele (NAT1*4) is present in the individual indicated by the open arrow in Figure 1(a). However, most other known NAT1 alleles (in which the primer N1113 does not generate an additional Mbo II restriction site) generate fragments of 176 bp and 144 bp, apart from NAT1*11, in which the corresponding fragment is 135 bp due to a 9 base pair deletion. In the case of the individual identified by the open arrow, an additional band of 116 bp was identified which was not consistent with any of the then-known alleles. To confirm whether this restriction pattern was due to the presence of a novel allele, the NAT1 alleles (a 1.6 Kb region) from the individual were cloned and sequenced. As a result, a novel allele was identified and defined as NAT1*11B (with C at 1095) due to its high sequence similarity with NAT1*11A (with A at 1095) (Figure 1(b)). NAT1*11B contains six mutations with respect to the NAT1*4 sequence: C-344T, A-40T, G445A (V149I), G459A, T640G (S214A), 9 bp deletion in the nucleotide region 1065-1090. The functional consequences of this allele are likely to be similar to that of NAT1*11A where an association with low enzymic activity has been proposed as a result of the amino acid changes V149I and S214A [42,43]. Other changes in the novel allele compared with NAT1*4 are outside the coding region (Figure 1(b)) and their effects have not yet been established. Although this allele was identified in an AD patient, it is unlikely to play a significant role in the pathogenesis of AD since it was found in only one individual.
###end p 49
###begin p 50
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(a) </italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo </italic>
###xml 194 200 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4</italic>
###xml 220 224 220 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mbo </italic>
###xml 263 267 263 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 373 380 371 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 469 475 467 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*3</italic>
###xml 477 494 475 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10, NAT1*14A</italic>
###xml 518 526 516 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11A</italic>
###xml 671 675 669 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(b) </italic>
###xml 680 685 678 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 839 847 837 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11B</italic>
###xml 909 914 907 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 922 929 920 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 983 988 981 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 996 1004 994 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11A</italic>
###xml 1006 1015 1004 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11B </italic>
###xml 1066 1075 1064 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*11A </italic>
###xml 1194 1201 1188 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*4 </italic>
###xml 1284 1289 1278 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
Identification of a novel NAT1 allele. (a) A 344 bp PCR product of NAT1 (amplified from genomic DNA using primers N769 and N1113, the latter introducing an additional Mbo II restriction site in NAT1*4) was digested with Mbo II and separated on a 4% (w/v) MetaPhor(R) agarose (FMC BioProducts, UK)/0.5X TBE gel, against a 1 kb DNA Ladder (Gibco BRL, UK)(Lane M). Detectable NAT1*4 fragments are 176 bp and 125 bp. Fragments of other known alleles are 176 bp and 144 bp (NAT1*3, NAT1*10, NAT1*14A) or 176 bp and 135 bp (NAT1*11A). The individual marked with an open arrow had a novel restriction fragment (116 bp) which did not correspond to any known allelic combination. (b) Both NAT1 alleles of the individual marked with an open arrow were sequenced across the coding and 5' and 3' flanking regions and the sequence of the novel allele (NAT1*11B) is illustrated in comparison with the most common Caucasian NAT1 allele, NAT1*4 (EMBL Accession Number AJ307007) and the most similar NAT1 allele, NAT1*11A. NAT1*11B contains sequence variations identical to those of NAT1*11A (C-344T, A-40T, G445A, G459A, T640G and a 9 base deletion (Delta) in the nucleotide range 1065-1090, compared with the NAT1*4 sequence), but contains a cytosine at nucleotide 1095. The 870 bp coding region of NAT1 is shaded grey, with 438 nucleotides upstream and 306 nucleotides downstream also shown.
###end p 50
###begin title 51
Conclusions
###end title 51
###begin p 52
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 209 214 209 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 438 447 438 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT 1*10 </italic>
In conclusion, the study presented here, which to our knowledge includes the first known investigation of the association between NAT1 genotype and susceptibility to AD, suggests that genetic polymorphisms in NAT1 and NAT2 do not influence susceptibility to AD. However, the inclusion of SNP analysis at positions 1088 and 1095 in a multi-variant analysis would be warranted based on the present studies since there is an indication that NAT 1*10 is elevated in AD.
###end p 52
###begin title 53
Competing interests
###end title 53
###begin p 54
None declared.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
NJ carried out the NAT1 and NAT2 genotyping and NAT1 sequence analysis, performed the statistical analysis and drafted the manuscript. PB and VJ participated in the NAT1 genotyping. MB participated in the design of the study and provided study samples. ES conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.
###end p 56
###begin title 57
Pre-publication history
###end title 57
###begin p 58
The pre-publication history for this paper can be accessed here:
###end p 58
###begin p 59

###end p 59
###begin title 60
Acknowledgements
###end title 60
###begin p 61
We are very grateful to The Wellcome Trust, Bristol-Myers Squibb and the MRC (Foresight Challenge Grant) for generous financial support. We thank Prof. A.D. Smith and his staff at OPTIMA for their co-operation as well as the individuals who provided the samples used in this study.
###end p 61
###begin article-title 62
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Force under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
###end article-title 62
###begin article-title 63
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
###end article-title 63
###begin article-title 64
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
###end article-title 64
###begin article-title 65
A familial Alzheimer's disease locus on chromosome 1
###end article-title 65
###begin article-title 66
Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease
###end article-title 66
###begin article-title 67
Molecular genetics of Alzheimer's disease
###end article-title 67
###begin article-title 68
Dementia of the Alzheimer type: clinical and family study of 22 twin pairs
###end article-title 68
###begin article-title 69
Clinical, neuroimaging, and environmental risk differences in monozygotic female twins appearing discordant for dementia of the Alzheimer type
###end article-title 69
###begin article-title 70
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease?
###end article-title 70
###begin article-title 71
Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease
###end article-title 71
###begin article-title 72
Serum folate and the severity of atropy of the neocortex in Alzheimer disease: findings from the Nun Study
###end article-title 72
###begin article-title 73
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 81 89 81 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 81 88 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterisation of its potential role in folate metabolism
###end article-title 73
###begin article-title 74
###xml 15 16 15 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells
###end article-title 74
###begin article-title 75
###xml 31 32 31 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Substrate selectivity of mouse N-acetyltransferases 1, 2 and 3 expressed in COS-1 cells
###end article-title 75
###begin article-title 76
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2</italic>
###xml 186 187 186 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 24 30 <span type="species:ncbi:10090">murine</span>
A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate
###end article-title 76
###begin article-title 77
###xml 38 39 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 65 70 <span type="species:ncbi:10090">mouse</span>
###xml 106 111 <span type="species:ncbi:10090">mouse</span>
Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain
###end article-title 77
###begin article-title 78
###xml 21 27 <span type="species:ncbi:9606">humans</span>
Acetyltransferase in humans: Development and tissue distribution
###end article-title 78
###begin article-title 79
###xml 38 39 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus
###end article-title 79
###begin article-title 80
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 69 70 69 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) or peripheral blood
###end article-title 80
###begin article-title 81
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease
###end article-title 81
###begin article-title 82
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2 </italic>
Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease
###end article-title 82
###begin article-title 83
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
N-acetylation pharmacogenetics
###end article-title 83
###begin article-title 84
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2</italic>
N-acetyltransferase (NAT2) genotype and susceptibility to sporadic Alzheimer's disease
###end article-title 84
###begin article-title 85
Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atropy by computed tomography
###end article-title 85
###begin article-title 86
CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia
###end article-title 86
###begin article-title 87
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer's disease
###end article-title 87
###begin article-title 88
Plasma total homocysteine and cognitive performance in a volunteer elderly population
###end article-title 88
###begin article-title 89
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 33 38 <span type="species:ncbi:9606">human</span>
Arylamine N-acetyltransferase in human red blood cells
###end article-title 89
###begin article-title 90
###xml 27 28 27 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 11 16 <span type="species:ncbi:9606">human</span>
Genotyping human arylamine N-acetyltransferase type 1 (NAT1). The identification of two novel allelic variants
###end article-title 90
###begin article-title 91
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 74 80 <span type="species:ncbi:9606">humans</span>
N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans
###end article-title 91
###begin article-title 92
###xml 39 40 39 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 11 16 <span type="species:ncbi:9606">human</span>
Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants
###end article-title 92
###begin article-title 93
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 42 45 <span type="species:ncbi:9606">men</span>
Arylamine N-acetyltransferases - of mice, men and microorganisms
###end article-title 93
###begin article-title 94
###xml 34 35 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 99 107 99 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1*10 </italic>
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2*4 </italic>
###xml 153 154 153 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 178 183 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT1 </italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NAT2</italic>
###xml 137 142 <span type="species:ncbi:9606">human</span>
Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2
###end article-title 94
###begin article-title 95
Xenobiotic metabolism in Alzheimer's disease
###end article-title 95
###begin article-title 96
Acetylator polymorphism in Alzheimer's disease
###end article-title 96
###begin article-title 97
###xml 103 111 103 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 136 139 <span type="species:ncbi:10116">rat</span>
An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomes
###end article-title 97
###begin article-title 98
###xml 79 84 <span type="species:ncbi:9606">human</span>
The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes
###end article-title 98
###begin article-title 99
###xml 18 19 18 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Identification of N-acetyltransferase 2 genotypes by continuous monitoring of fluorogenic hybridisation probes
###end article-title 99
###begin article-title 100
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility
###end article-title 100
###begin article-title 101
###xml 76 77 76 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene
###end article-title 101
###begin article-title 102
Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function
###end article-title 102
###begin article-title 103
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients
###end article-title 103
###begin article-title 104
###xml 117 118 117 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 141 149 141 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-vivo </italic>
###xml 153 162 153 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in-vitro </italic>
###xml 58 63 <span type="species:ncbi:9606">human</span>
Identification and characterisation of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe
###end article-title 104

